1Bubley GJ,Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group[J]. J Clin Oncol, 1999,17 (11) :3461- 467. 被引量：1
2Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recom- mendations for the treatment of prostate cancer[J]. Urol Int, 2004,72 (2) :91-98. 被引量：1
3Small E J, Halabi S, Dawson NA,et al. Antiandrogen withdrawal a- lone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase Ⅲ trial (CALGB 9583)[J]. J Clin 0ncol,2004,22 (6) : 1025-1033. 被引量：1
4Attard G, Reid AH, Olmos D,et al. Antitumor activity with C YPI7 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven [J]. Cancer Res, 2009,69 (12):4937 4940. 被引量：1
5Hartmann RW, Ehmer PB, Haidar S, et al. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer [J]. Arch Pharm (Weinheim) ,2002,335 (4):119-128. 被引量：1
6Berthold DR, Sternberg CN, Tannoek IF. Management of advanced prostate cancer after first-line chemotherapy [J]. J Clin Oncol, 2005,23 (32):8247-8252. 被引量：1
7Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitox- antrone plus prednisone or prednisone alone for symptomatic hormone- resistant prostate cancer: a Canadian randomized trial with palliative end points [J]. J Clin Oncol, 1996,14 (6):1756-1764. 被引量：1
8Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer [J]. Can J Urol,2006,13(6):3335-3339. 被引量：1
9Petrylak DP, Tangen CM, Hussain MH,et al. Docetaxel and estra-mustine compared with mitoxantrorte and prednlsone for advanced re- fractory prostate cancer[J]. N Engl J Med, 2004,351(15):1513 1520. 被引量：1
10Tannock IF, de Wit R, Berry WR,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004,351 (15) :1502-1512. 被引量：1
